Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBOS Group Limited ( (AU:EBO) ) just unveiled an update.
EBOS Group Limited has disclosed a change in director Stuart McLauchlan’s relevant interest in the company’s ordinary shares, resulting from participation in a dividend reinvestment plan. McLauchlan’s indirect holding, beneficially owned but registered under JBWere (NZ) Nominees Limited, increased by 134 ordinary shares on 27 March 2026, taking his total interest to 5,320 shares.
The additional shares were issued at a value of NZ$2,960.06 under the dividend reinvestment plan, with no shares disposed of and no changes reported in any related contracts. The company confirmed the transactions did not occur during a closed period requiring prior written clearance, underscoring compliance with ASX director trading and disclosure requirements and maintaining transparency for shareholders about incremental changes in board members’ holdings.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$29.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a listed company that operates in the healthcare and related sectors, though this notice focuses solely on director shareholdings rather than operational details. The filing is made under ASX listing rules governing disclosure of directors’ interests, ensuring transparency for investors and regulators regarding changes in director equity positions.
Average Trading Volume: 154,755
Technical Sentiment Signal: Sell
Current Market Cap: A$3.82B
For detailed information about EBO stock, go to TipRanks’ Stock Analysis page.